"Platelet Rich Plasma" (PRP) is a ubiquitous term for a type of therapy that applies autologous platelets collected from whole blood and then concentrated via centrifuge that are re-applied to injured musculoskeletal tissue. The intent of most PRP therapies is to locally create or support a "healing response," that instigates earlier healing, or to initiate a response in chronic degenerative and painful tissue. Complicating research efforts are the high number of different types and methods of PRP therapies, and the multiple anatomic and tissue sites of treatment that may potentially benefit from PRP. One of the greatest challenges in the development of PRP therapy have been translating promising laboratory and animal study results to clinical studies' outcomes. While enthusiasm for PRP therapy has often exceeded the evidence to support therapeutic benefits, recent studies and experience does support the use of specific types of PRP therapy in specific degenerative and injury patterns.
Introduction
Recovery from musculoskeletal injuries at times can be a slow and incomplete process leading to prolonged time away from work, sport, and loss of functional capacity. The repair process after injury starts with the inflammatory process, and is regulated by complex interactions of multiple growth factors to help restore damaged tissue. Over the last decade, efforts to improve or expedite healing injuries in the musculoskeletal system have focused on applying these growth factors. PRP has gained traction in research and treatment efforts as PRP provides a relatively simple, low cost, and fairly easy mode to acquire these growth factors in what is assumed to be physiologically balanced concentrations that can then be applied to damaged tissue. PRP is obtained from a patient's own whole blood (typically 15-60cc) that is centrifuged once or twice to separate out platelets with (double spin) or without (single spin) white blood cells, with concentrations anywhere from twice to nine times normal concentrations. It is most often mixed with an exogenous activator of platelets (ex: thrombin, calcium chloride, calcium citrate) which causes release of alpha granules from the platelets containing multiple cytokines and growth factors. The activated platelet concentrate is then injected into a damaged musculoskeletal tissue site (tendon, muscle, joint/cartilage, etc.) to either activate or enhance a "healing response." In more acute settings, endogenous activation relies on the platelet concentrate being activated when coming in contact with damaged collagen or other musculoskeletal tissue. Protocols call for either 1 to 4 injections spread out at least 4 to 7 days based upon evidence that release of cytokines and growth factors primarily occur in the first hours after injection, while platelet viability and cytokine release continues up to seven days after activation. (Marx, 2004) Categories of PRP application fall into the 4 areas: chronic tendinosis, acute ligament injury, muscle injury, and intraoperative tissue repair augmentation. (Hsu et al., 2013) Enthusiasm for clinical use and application of PRP has often outpaced solid evidence to support its use. (Sampson, Gerhardt, & Mandelbaum, 2008) The typical pattern in PRP research has shown very promising results in laboratory and animal studies, but translation of PRP therapy to clinical trials has been at times disappointing. (Robins, 2014) However 
Basic Science of PRP
PRP falls under a class of therapeutic approaches termed "biologics," which refers to using natural products to augment the physiological process of healing. At times, PRP may be classified under the umbrella of "prolotherapy" or "regenerative medicine," but PRP does not precisely meet the definition or the intent of these therapeutic philosophies. From a regulatory standpoint, the FDA defines "biologics" or biologic therapy as requiring minimal manipulation of an autologous source of cellular treatment, and whose efficacy does not relate to the metabolic activity of the cells being applied for therapy. PRP therapy is based on the premise that it benefits musculoskeletal tissue healing due to the high concentration of cytokines and growth factors that normally are involved in the initial and follow-on stages of the inflammatory process at recruiting and stimulating cell proliferation as well as producing extra-cellular matrix proteins. (Anitua et al., 2006; Williams et al., 2015) A list of these growth factors and cytokines are listed in Table 1 . While the theoretical advantage of using PRP administers these growth factors in physiological concentrations relative to each other, the reality is that these concentrations vary depending of the method of PRP preparations, amount of whole blood used, type of platelet activation, and the final total volume of PRP injected.(Fitzpatrick, Bulsara, McCrory, Richardson, & Zheng, 2017) In addition, the concentration of platelets and associated cytokines varies between patients, and even within the same patient at different points in time. (Creaney & Hamilton, 2008; Mazzocca et al., 2012) In other words, a patient receiving a series of treatment of 3 PRP injections one week apart, even when standardizing for type of PRP preparation, activation, and volume administered, will receive different concentrations of platelets in each of the PRP injections due to the variability of available platelets and leukocytes in the whole blood obtained from the patient at the time of collection.
Challenges in PRP Research
Many factors make interpreting and applying PRP research results challenging to clinical application. Two of these biggest factors include the plethora of different PRP preparations available for use, and the challenge of translating the success found in laboratory and animal research to clinical outcomes.
PRP Preparation Variability
PRP encompasses many variations of preparation methods, but can be best divided into plasma-based and "buffy-coat" based preparations. Plasma-based preparations are a result of a "single-spin" centrifuge process, which separates out and concentrates red blood cells, the "buffy coat" made up of white-blood cells, and plasma, which contains platelets concentrated on average between 2-5 times that of whole blood (Figure 1) . If the preparation undergoes a second centrifuge spin (double spin), this serves to concentrate the platelets even further, resulting in a "platelet-rich" and a "platelet-poor" plasma, but also include leukocytes in the platelet rich portion of the plasma. This results in different effects from the prepared PRP, with plasma based, single-spin PRP preparations demonstrating anabolic and cartilage extra-cellular-matrix stabilization effects, while white blood cell-containing double-spin PRP preparations create a stronger inflammatory and catabolic response. (Braun, Kim, Chu, & Dragoo, 2014) As a result, the indications of treatment may dictate that different preparations may provide a better response based upon the tissue environment and pathology being treated. 
Challenges with Comparison Analysis
When evaluating results of PRP, it is imperative to determine the type of preparation of PRP used. Mishra 
Current Clinical Applications
In addition to the multitude of PRP preparations, the different sites and types of injured tissue make comparison of PRP difficult. However, recent advances in specific pathologies has shown promising results, in particular for the treatment of mild to moderate degenerative joint disease of the knee, lateral epicondylitis, and patellar tendinitis. Other areas of treatment have included muscle belly injury, and surgical augmentation, in particular with rotator cuff tendon repair and anterior cruciate ligament reconstruction.
Knee Osteoarthritis
Use of PRP in preclinical data provided evidence that single spin, leukocyte poor preparations of PRP reduced inflammatory cytokines (in particular IL1b), and helped to stabilize the extracellular matrix of damaged hyaline cartilage. 
Patellar Tendinosis
Initial clinical results demonstrated promise for using PRP in patellar tendinosis. A pilot study of 20 patients with refractory "jumper's knee" were treated with 3 injections using 5mL of a double-spin, leukocyte-rich PRP (6x concentration of platelets) preparation activated with calcium chloride with 15 days in-between each injection.(Kon et al., 2009) At 6 months, statistically significant clinical improvements were noted in all factors including physical functional, with 80% of participants returned back to sport 4 months after therapy was administered. A follow-on comparative study evaluated patients refractory to established physical therapy treated with the same type of PRP as noted above with physical therapy only. The study demonstrated improved outcomes at 6 months in outcomes and pain scores in the study group, which represents a difficult patient cohort to successfully treat. ( Using 3 injections of leukocyte poor PRP (ACP) in a prospective study, 75% of patients had the ability to return to sports, with 57% of patients demonstrating complete resolution of tendon structure at 3 months from treatment. At 2 years, all patients were satisfied with the procedure with significant improvements in outcomes and pain scores. 
Achilles Tendinosis
Use of PRP in the treatment of Achilles tendinosis has been disappointing. 
Muscle injury
Treatment of muscle injury has been proposed to potentially benefit from PRP therapy. While regeneration of muscle tissue is possible after fetal development, many intra-muscular injuries heal with the development of a dense fibrotic scar, which forms at 7-14 days after injury. Therefore, an important aspect that has yet to be ascertained is the timing and appropriate dosing of growth factors to help modulate this process. There is also appropriate concern that the application of PRP may in fact promote the formation of fibrosis and scar due to the high concentrations of growth factors contained in PRP. Another factor limiting use of PRP in muscle injury is that the World Anti-Doping Agency (WADA) has listed PRP intramuscular injections as a prohibited intervention for athletes, due to the possible systemic anabolic effects of PRP, making this therapy for muscle injury limited to sports not regulated by WADA. 
Hamstring Injury
Hamstring injuries are one of the most common injuries encountered in sports medicine. Despite the high number of injuries, treatment is restricted to physical therapy and conservative measures. Time away from sports can typically be 6 weeks, and risk of recurrent injury persists during the first season following recovery. Initial In the Dutch-HIT study, there was no difference in return to play or difference in 1 year re-injury rate in their double-blind randomized control trial using 2 injections of the same type of single-spin leukocytepoor PRP (ACP) used in Mejia and Bradley's study. The difference between these two studies is that the latter study initiated the 1 st injection within 5 days after injury, while Mejia and Bradley administered the first injection 24-48 hours after injury. Hamid et al. in a randomized control trial conducted in Malaysia used a single 3mL leukocyte-rich PRP injection given between 1-7 days after injury and compared to a physical rehabilitation group. Zanon and colleagues from Italy performed a leukocyte-rich series of 2 or 3 PRP injections starting 24-48 hours after injury in professional soccer football players, and found PRP did not shorten return to sport, had a 12% recurrent injury rate, but did lead to a smaller scar at the injury site on followup imaging studies. (Zanon et al., 2016) A recent meta-analysis showed no effect of PRP therapy on acute hamstring injury, and identified improved study design for future research efforts. (Pas et al., 2015) The concern with PRP for hamstring muscle injury therapy is confounded by not only preparation variation and number of injections, but also timing for initiation of treatment before stronger recommendations can be made regarding the use of PRP for treatment of acute hamstring injury.
Surgical Augmentation
Use of PRP therapy for surgical augmentation has initially demonstrated promise in pre-clinical studies, but to date, there has been no conclusive data to suggest efficacy or benefit in terms of clinical outcomes. (Robins, 2014) Two main areas of focus have been in anterior cruciate ligament reconstruction (ACL) surgery and rotator cuff repair.
Anterior Cruciate Ligament Reconstruction
Multiple studies have evaluated the effects of PRP on ACL graft maturation which would presume better healing and lower re-tear rates. A recent systematic review concluded that PRP may provide a 20-30% beneficial effect on graft maturation, but that there is no evidence of significantly-improved healing compared to the control group at 6 months on MRI. However, one of the limitations to de Almedia et al.'s application of PRP is that 50mL of PRP was applied to the harvest site, which requires 450mL of blood volume be at least temporarily withdrawn for preparation of this large volume of PRP. In Sejia and colleagues study, only 4cc of PRP (PRGF) was applied to the donor sites, which reduced pain during the first 2 months compared to the control group. While use of PRP may reduce pain in the postoperative period, further research is needed to determine if the cost-effectiveness of this application of PRP is a reasonable option.
Rotator Cuff Repair
PRP applied to augment rotator cuff repair has followed the pattern of early promising results in pre-clinical and laboratory data, but without demonstrating benefit with application in clinical series. (Robins, 2014) In a randomized control trial, application of PRP fibrin matrix (PRFM) to the rotator cuff repair site was found to correlate with worse healing rates, indicating the possibility the PRP gel interfered rather than benefited tendon-tobone healing. (Rodeo et al., 2012 ) Out of 18 randomized control trials on PRP augmentation in rotator cuff repair, 10 demonstrated no differences between intervention and control groups, 2 demonstrated improved pain control during the 1 st two months after surgery, and 5 showed lower re-tear rates on imaging but not necessarily any difference in clinical outcomes. (Filardo et al., 2016) The high degree of heterogeneity in application and types of injections utilized in rotator cuff repair make interpreting which type of PRP and when to inject difficult to determine. In addition the cost-effectiveness of adding PRP to rotator cuff repair would have to show at least a reduced re-tear rate of 9.1% to be worth adding to surgical treatment. (Samuelson, Odum, & Fleischli, 2016 ) Metanalysis demonstrated PRP had no effect on large rotator cuff repairs, did help in small and medium tears at reducing re-tear rate, but was too costly to make adding PRP to this cohort of injury justifiable. (Vavken et al., 2015) 6. Conclusion PRP, as a biologic therapy, presents the possibility of benefit to multiple musculoskeletal injury sites.
Use of leukocyte-poor PRP in the treatment of knee osteoarthritis has demonstrated significant benefits in multiple trials and case series. Use of PRP in the treatment of lateral epicondylitis, in particular with leukocyterich preparations, had some evidence to support its use for therapeutic benefit. A small amount of evidence supports the possibility of PRP helping in treating partial UCL tears in the elbow. There is also limited evidence to consider the use of PRP in the management of patellar tendinosis. Most evidence supports not using PRP in the treatment of Achilles tendon partial tears or tendinopathy. Use of PRP in muscle injury and specifically in hamstring injury has mixed results in the data, and it appears that besides type and number of injections, the timing of PRP injections is important in promoting muscle regeneration versus inadvertently stimulating increased fibrosis across the injury site. Finally, PRP in augmenting ACL and rotator cuff tendon repair have mixed results and cannot be recommended for routine use at this point in time.
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